SCHEMBL4887408

SCHEMBL4887408

O=Cc1ccc(-c2ccc(O)cc2)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH5A1 P51649 1/20 0.52
ABAT P80404 1/20 0.52
ALDH1A1 P00352 1/20 0.52
ESR1 P03372 6/20 0.47
ESR2 Q92731 4/20 0.47
HSD17B1 P14061 1/20 0.45
HSD17B2 P37059 1/20 0.45
ALDH1A3 P47895 1/20 0.45
KDM4E B2RXH2 1/20 0.42
PTGS2 P35354 1/20 0.42
RAB9A P51151 1/20 0.42
HSD17B10 Q99714 1/20 0.41
PELI1 Q96FA3 1/20 0.40
TTR P02766 1/20 0.40
BACE1 P56817 1/20 0.40
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
PTPN11 Q06124 2/20 0.39
NR0B2 Q15466 1/20 0.39
VCAM1 P19320 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30185447 0.81 ALDH1A1 (0.55) ALDH1A1ESR1ALDH1A3KDM4EHSD17B10
SCHEMBL30185446 0.81 ALDH1A1 (0.55) ALDH1A1ESR1ALDH1A3KDM4EHSD17B10
SCHEMBL4035480 0.81 ALDH1A1 (0.55) ALDH1A1ESR1ALDH1A3KDM4EHSD17B10
SCHEMBL4892926 0.79 ESR1 (0.54) ALDH1A1ESR1ESR2HSD17B1HSD17B2
SCHEMBL4892962 0.79 ESR1 (0.54) ALDH1A1ESR1ESR2HSD17B1HSD17B2
SCHEMBL3290498 0.79 PTPN11 (0.60) ALDH1A1ESR1ESR2KDM4EHSD17B10
SCHEMBL4894861 0.79 ALDH5A1 (0.52) ALDH5A1ABATALDH1A1ESR1ESR2
SCHEMBL27380398 0.79 ALDH5A1 (0.52) ALDH5A1ABATALDH1A1ESR1ESR2
SCHEMBL4892898 0.79 ALDH5A1 (0.52) ALDH5A1ABATALDH1A1ESR1ESR2
SCHEMBL3684267 0.78 ESR1 (0.70) ESR1ESR2HSD17B1HSD17B2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620392-B1 HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS WYETH CORP (US) 2007-06-27 EP claimed
US-20080033049-A1 Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents WYETH (US) 2008-02-07 US disclosed
US-20080033049-A1 Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents WYETH (US) 2008-02-07 US disclosed
US-20080033049-A1 Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents WYETH (US) 2008-02-07 US disclosed
US-7279600-B2 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents WYETH (US) 2007-10-09 US disclosed
US-7279600-B2 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents WYETH (US) 2007-10-09 US disclosed
US-7279600-B2 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents WYETH (US) 2007-10-09 US disclosed
EP-1808429-A2 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents Wyeth a Corporation of the State of Delaware (US) 2007-07-18 EP disclosed
EP-1808429-A2 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents Wyeth a Corporation of the State of Delaware (US) 2007-07-18 EP disclosed
EP-1620392-B1 HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS WYETH CORP (US) 2007-06-27 EP disclosed
EP-1620392-B1 HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS WYETH CORP (US) 2007-06-27 EP disclosed
EP-1620392-A2 HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS Wyeth (US) 2006-02-01 EP disclosed
US-20050020676-A1 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents WYETH 2005-01-27 US disclosed
WO-2004099122-A2 HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS WYETH (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033049-A1 Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents ESR1, ESR2, ESRRB ALDH5A1 861/4885ABAT 3701/4885ALDH1A1 348/4885
US-20050020676-A1 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents ESR1, ESR2, ESRRB ALDH5A1 861/4885ABAT 3701/4885ALDH1A1 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.